Publications

Search for Publications

List of Publications

Sort by: Date | Author | Title

Jensen, C. B., Hansen, K. T., Bech, B. H., Hansen, S. N., Nielsen, H., Rask, C. U., Fink, P., Dantoft, T. M., Jørgensen, T., Labrecque, J. A., Thysen, S. M. & Rytter, D. (2025). Post-acute non-specific symptoms following COVID-19 vaccination: a Danish population-based study. International Journal of Epidemiology, 54(5), Article dyaf173. https://doi.org/10.1093/ije/dyaf173
Søby, S., Prestwich, R., Gyldenkerne, N., Maare, C., Lonkvist, C. K., Andersen, M., Nowicka-Matus, K., Gothelf, A., Tramm, T., Toustrup, K., Mihaela, S., Ulahannan, D., Iyizoba-Ebozue, Z. & Eriksen, J. G. (2025). Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study. Acta Oncologica, 64, 1269-1275. https://doi.org/10.2340/1651-226X.2025.44327
Mondin, A., Barbot, M., Ceccato, F., Pereira, A. M., Angelousi, A., Elenkova, A., Zilaitiene, B., Schalin-Jäntti, C., De Herdt, C., Kanaka-Gantenbein, C., Maiter, D., Gatto, F., Johannsson, G., Stochholm, K., Bugalho, M. J., Detomas, M., Reincke, M., Toumba, M., Giordano, R. ... Scaroni, C. (2025). European survey on metabolic and cardiovascular risk in Cushing syndrome. Journal of Endocrinological Investigation, 48(11), 2657-2670. https://doi.org/10.1007/s40618-025-02663-9
Baygi, F., Brandt, C. J., Kjær-Hansen, K., Grøntved, A., Brønd, J. C., Nicolaisen, S. K., Stidsen, J. V., Thomsen, R. W., Søndergaard, J. & Nielsen, J. S. (2025). Participation of individuals with type 2 diabetes in a behavioural e-health lifestyle intervention in Denmark: A feasibility study. Diabetes Epidemiology and Management, 19-20, Article 100285. https://doi.org/10.1016/j.deman.2025.100285
Højte, C., Olsen, M. F., Faurholt-Jepsen, D., Jørgensen, M. H., Pressler, T., Leo-Hansen, C., Bryrup, T., Jeppesen, M., Olesen, H. V., Petersen, J., Katzenstein, T. L., Nielsen, B. U., Skov, M. & the TransformCF study group (2025). Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort. Journal of Cystic Fibrosis, 24(5), 998-1005. https://doi.org/10.1016/j.jcf.2025.08.008